Detalhe da pesquisa
1.
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma.
Blood
; 2024 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38768337
2.
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Br J Haematol
; 192(5): 869-878, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33216361
3.
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Blood
; 134(8): 668-677, 2019 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31270103
4.
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).
Haematologica
; 106(6): 1725-1732, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32354874
5.
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Blood Cancer J
; 14(1): 24, 2024 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38307865
6.
Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma.
Clinicoecon Outcomes Res
; 13: 465-473, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34135605
7.
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
J Cancer Res Clin Oncol
; 147(2): 619-631, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32852632
8.
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Lancet Haematol
; 7(5): e370-e380, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32213342
9.
Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Blood Cancer J
; 14(1): 40, 2024 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38448422
10.
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.
Leuk Lymphoma
; 59(12): 2888-2895, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29846137
11.
Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.
J Rheumatol
; 42(10): 1752-60, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26233509
12.
Pharmacokinetics and safety of golimumab in healthy Chinese subjects following a single subcutaneous administration in a randomized phase I trial.
Clin Drug Investig
; 33(11): 795-800, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23975656